E-learningNews & eventsSpeakersPartners
Sign in
Sign in
Social media
Main pages
  • News & events
  • Speakers
  • Partners
  • Reviews
E-learning
  • Courses
  • Lectures
Corporate website
  • Sona Group

Contacts

  • info@sona-pharm.eu
  • Business days 9:00-17:00 EET
  • +372 505 9699
  • Ahtri 6, Tallinn, 10151, Estonia

Sona Group unites a network of independent pharmaceutical and healthcare companies operating in research, manufacturing and continued medical education.

This website is intended for informational and corporate communication purposes only and is not a substitute for medical advice.

© 2026 Sona Academy®. All rights reserved.

··Site map
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Legal Notice
  • Professional Medical Disclaimer
  • Data Collection and Privacy Disclaimer
Reproductive healthLecture

Thin endometrium — should embryo transfer be cancelled?

28 minAudio: EN · UA · RUSubtitles: EN · UA · RU
Player.aboutHeading

Few practices in reproductive medicine are as widely accepted yet as poorly evidenced as the cancellation of embryo transfer for thin endometrium. The lecture proposes a logical framework — four sequential questions — that must all be answered convincingly before cancellation can be justified. None of the four, on closer examination, holds up.

Question one: is the endometrium really «thin»?

There is no biological consensus on the threshold. The literature cutoffs span 6 to 14 mm, with the widely-quoted 7 mm threshold tracing back to a small cohort study from the late 1980s, when vaginal ultrasound was not yet standard and sample sizes were modest. Live births at thickness below 4 mm have been published. The threshold is convention, not biology.

Question two: is thin endometrium causally linked to lower live birth?

Two opposing pathophysiological theories coexist in the literature. One holds that thin endometrium reflects poor vascularisation and low oxygen — bad for the embryo. The other holds that thin endometrium places the embryo too close to the basal layer, causing hyperoxia and oxidative damage — also bad for the embryo. Neither has been demonstrated convincingly, and they point in opposite mechanistic directions.

Question three: methodological problems in the literature

Thickness studies suffer from inconsistent measurement timing (trigger day vs OPU vs ET), inflated statistical significance from massive registry sample sizes that translate to clinically trivial effect sizes, and severe practice-pattern contamination — units that already cancel thin endometrium do not contribute thin cases to the denominator. Inter-observer measurement variability of several millimetres further undermines the precision needed for clinical thresholds.

Question four: do we have a proven thickening intervention?

No therapy currently in clinical use has been shown to reliably increase endometrial thickness with a corresponding live-birth gain. Patients are often subjected to repeated «endo prep» cycles without any proven intervention — losing time and emotional investment without measurable benefit.

Outcomes when transfer proceeds anyway

Prospective and multicentre data — including a large multicentre study of euploid blastocyst transfers — show that when transfer proceeds regardless of thickness (after excluding intracavitary pathology and premature progesterone exposure), live birth rates at <7 mm remain in the 42–47% range. Cancellation guarantees zero. Proceeding offers a substantial probability of pregnancy.

Clinical takeaway

Replace mm-based cancellation rules with a structured exclusion checklist: intracavitary pathology, scarring, infection and premature progesterone exposure. If these are addressed, the residual «thinness» does not justify cancellation. Counsel patients with realistic outcome data, not with mm-thresholds inherited from the 1980s.

Topics covered
  • Four-question logic chain for cancellation
  • Arbitrariness of the 7 mm threshold
  • Methodological problems in thickness literature
  • Inter-observer measurement variability
  • Practice-pattern contamination of registries
  • Live birth rate at <7 mm (42–47%)
  • Causes of thinness (scarring, infection, idiopathic)
Watch the lesson
About the course

Thin endometrium remains one of the most debated topics in reproductive medicine. Is it justified to cancel transfer at a thickness of <7 mm? Analysis of the evidence base — from classical work of the late 1980s to current multicentre cohorts (~30,000 cycles) — shows that with proper work-up (exclusion of intracavitary pathology and premature progesterone exposure), the live birth rate at thickness <7 mm remains in the 42–47% range.

Thin endometrium remains one of the most debated topics in reproductive medicine. Is it justified to cancel transfer at a thickness of <7 mm? Analysis of the evidence base — from classical work of the late 1980s to current multicentre cohorts (~30,000 cycles) — shows that with proper work-up (exclusion of intracavitary pathology and premature progesterone exposure), the live birth rate at thickness <7 mm remains in the 42–47% range.

What you will learn

Apply the four-question logic chain for cancellation

Cancellation is only justified when all four prerequisite questions are convincingly answered yes.

Critically evaluate thickness thresholds

Recognise that 6–14 mm cutoffs in literature reflect practice patterns, not biology.

Address inter-observer measurement variability

Single-millimetre thresholds are not reproducible enough to drive clinical decisions.

Counsel patients with realistic outcome data

Live birth rate at <7 mm remains in the 42–47% range with proper exclusion of pathology.

Who is this course for
  • Reproductive endocrinologists and ART specialists
  • Gynecologists managing infertility patients
  • ART fellows and embryologists with clinical focus
Baris Ata

Baris Ata

Dean of Koç University School of Medicine, and Professor and Head of its Department of Obstetrics and Gynecology. A reproductive endocrinology and infertility subspecialist focusing on female infertility, IVF and endometriosis. Holds leadership positions in international fertility societies and serves as an editor for international journals.

Author of the lecture "Thin endometrium — should embryo transfer be cancelled?"

Continue your learning

View all programs
View all programs
Sona Academy Online Webinar
Webinar • AI in Reproductive Medicine
45d 4hReproductive healthLecture

AI in Reproductive Medicine

Patients arrive at the clinic already having consulted ChatGPT, and regulators are reviewing the first AI ‘doctors’. What in artificial intelligence already works in reproductive medicine — from assistant avatars to embryo assessment and stimulation personalisation? A live discussion on three levels — strategy, service and clinic — with practical cases and a panel Q&A.

Christos Venetis
Christos Venetis
Sona-Pharm grant award • Ceremony — July 2027, Stockholm
Fertility Award 2027 • Applications open 1 Feb 2027
280d 21hReproductive healthLecture

Fertility Award 2027

A Sona-Pharm grant award for specialists in infertility treatment. Applications open on 1 February 2027. Ceremony — July 2027, Stockholm, during the ESHRE meeting.

Mykola Gryshchenko
Mykola Gryshchenko
UARM Symposium • 22.05.2026
Lecture • Immunotropic therapy in reproductive medicine
Reproductive healthLecture

Immunotropic therapy in reproductive medicine

Targeted, biomarker-guided immunotropic therapy in reproductive medicine. A lecture by Kseniia Khazhylenko at the UARM Symposium 2026.

Audio: UASubtitles: UA32 min

Kseniia Khazhylenko
Kseniia Khazhylenko